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ABSTRACT
Cancer is among the major causes of human death
and its mechanism(s) are not fully understood. We
applied a novel meta-analysis approach to multiple
sets of merged serial analysis of gene expression
and microarray cancer data in order to analyze tran-
scriptome alterations in human cancer. Our method-
ology, which we denote ‘COgnate Gene Expression
patterNing in tumours’ (COGENT), unmasked
numerous genes that were differentially expressed
in multiple cancers. COGENT detected well-known
tumor-associated (TA) genes such as TP53, EGFR
and VEGF, as well as many multi-cancer, but
not-yet-tumor-associated genes. In addition, we
identified 81 co-regulated regions on the human
genome (RIDGEs) by using expression data from
all cancers. Some RIDGEs (28%) consist of paralog
genes while another subset (30%) are specifically
dysregulated in tumors but not in normal tissues.
Furthermore, a significant number of RIDGEs are
associated with GC-rich regions on the genome.
All assembled data is freely available online (www
.oncoreveal.org) as a tool implementing COGENT
analysis of multi-cancer genes and RIDGEs. These
findings engender a deeper understanding of cancer
biology by demonstrating the existence of a pool of
under-studied multi-cancer genes and by highlight-
ing the cancer-specificity of some TA-RIDGEs.
INTRODUCTION
Cancer is still one of the most fatal diseases in the
industrialized world. Cancer cells utilize an unbalanced
state in the genome, epigenome and transcriptome to
survive and proliferate, leading to the death of the host
through multiple processes. Transcriptomes of cancers are
being increasingly analyzed through the use of micro-
arrays and other methods, including serial analysis of
gene expression (SAGE) (1), SAGE data produced by
new generation sequencing technologies (tag-Seq), (2)
and RNA-Seq. This rich data cloud in turn lends itself
well to cross-sectional studies that focus on identifying
genes that are differentially expressed in multiple studies
and multiple cancers. Rhodes et al. (3) ﬁrst demonstrated
that some gene expression changes are common to
cancers. This concept was later extended and expanded
(4). These studies showed that cancer gene expression
patterns can sort cancer and normal tissue when used as
a diagnostic signature. Results derived from such gene
expression studies led to the ﬁrst United States Food
and Drug Administration approved gene expression sig-
nature based test, Mammaprint (5). Mammaprint predicts
therapy outcome in breast cancer, providing a good
example of the predictive power of gene expression signa-
tures. In extending the concept further, another study (6)
compared tissue- and cancer-speciﬁc gene expression to
show that melanomas over-express more brain selective
genes than other types of cancer, which the authors
hypothesized might explain melanoma metastasis to the
brain as a frequent outcome. Other studies utilizing
similar approaches have shown that E2F transcription
factor is likely mediating gene over-expression in most
human cancers (7). In spite of the explanatory power of
using gene expression signatures for diagnosis and classi-
ﬁcation, therapeutic targeting of even single genes is still a
nascent ﬁeld. Therefore, it is of great importance to
identify novel cancer genes and gene variants as targets
of therapy. Moreover, in spite of the popularity and avail-
ability of microarray technology, which has formed the
basis of most earlier cross-sectional studies, sequencing
based methods have the advantage of enabling analyses
of both known and novel genes since they are not depend-
ent on pre-selected probes. Information derived from
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based methods by highlighting, for example, the involve-
ment of differentially expressed splice-variants.
Co-regulation of proximate genes points to another,
higher order control of gene expression. Cohen et al. (8)
ﬁrst elucidated the co-regulation of adjacent yeast gene
pairs or triplets by comparing different data sets, such as
cell cycle time course (14% of genes co-regulated) and
sporulation (23% of genes co-regulated). Later, Caron
et al. (9) deﬁned regions of increased gene expression
(RIDGEs) along chromosomes by analyzing SAGE
libraries from different human tissues. This was followed
by demonstration of large domains (10–30 genes) of
co-regulation in Drosophila, which comprised 20% of all
genes on the fruit-ﬂy genome (10). And recently, Stransky
et al. (11) identiﬁed RIDGEs within human bladder
cancers and matched normals. Some of these RIDGEs
were explained by chromosomal ampliﬁcations/deletions,
but some of the RIDGEs were not. As data from develop-
ing high throughput methods accumulate, identiﬁcation of
genomic regions with similar regulation patterns becomes
more useful in determining which, if any, transcriptional
or epigenetic events may be involved in generating such
co-regulation.
Considering the above studies and observations, we per-
formed a meta-analysis of gene expression in cancer
tissues along with matched normal tissues using integrated
SAGE and microarray data. We found that over-
expressed multi-cancer genes are signiﬁcantly enriched
for article annotations in spite of having a high ratio of
not yet tumor-associated (NYTA) genes. In addition, we
expanded our analysis to identify TA regions of increased
gene expression (TA-RIDGEs) in comparison to Normal
tissue-Associated RIDGEs (NA-RIDGEs). We borrowed
the acronym RIDGE from Caron et al.’s concept, even
though we studied regions of co-regulated differential
expression. As well as showing the G/C richness of
RIDGEs, we point to the distinct expression of a
subgroup of the keratin gene family compared to epider-
mal differentiation complex (EDC) (12) expression in skin
cancers. Finally we make all of our data publicly available
in an online tool, oncoreveal (http://www.oncoreveal.org).
METHODS
Data collection and processing
In total 170 normal and 132 cancer SAGE libraries
representing 32 different types of cancers, as well as 477
normal and 927 cancer microarray samples representing
37 different types of cancers were analyzed. In order to
merge SAGE and microarray data, we mapped micro-
array probes and SAGE tags to Entrez Gene IDs. In
total, this corresponds to 49 different types of tumors
comprising four major types of human cancer, which are
epithelial, hematological, central nervous system and con-
nective tissue tumors. This data has been published in at
least 32 separate articles (see Supplementary Tables S2
and 3 for lists and references). Of the 37 microarray
data sets, 25 were downloaded from Oncomine. The rest
was collected from the Entrez GEO database. In order to
make the GEO data comparable to oncomine data, data
was log2 transformed and median was set to 0 by subtract-
ing ‘median of all samples’ from each data point, and SD
was set to 1 by dividing each data point to standard de-
viation among all samples in the study. A Benjamini–
Hochberg corrected P-value (Q-value) for multiple hy-
pothesis testing (13) was calculated as the corrected P-
value obtained from student’s t-test as in (3). To
maximize data retrieval, we used an iterative extraction
process that scans through different Entrez Gene
releases to convert Oncomine released gene symbols to
Entrez Gene IDs (Supplementary Data). During
pre-processing, probesets matching to multiple genes (in
average 1%) or probesets matching to ESTs or
non-matching probesets (in average 22%) were discarded
(Supplementary Table S2B).
If multiple probesets matched to a single gene, we con-
sidered the average fold, P- and Q-values of multiple
probesets that pointed in the same direction (over or
under expression). If there were probesets which pointed
in both directions, we considered that gene as both over
and under-expressed in the cognate gene expression pat-
terning in tumours (COGENT) procedure, which might be
explained by multiple isoforms of the same gene.
Digital Gene Expression Display (DGED) tool was
used to ﬁnd differentially expressed SAGE tags between
several different tumors and corresponding normals.
DGED is one of the tools under the SAGE Genie (14)
web platform founded to analyze CGAP data. The two
parameters of output in DGED are the F- and P-values;
which are statistical parameters to deﬁne the stringency of
differential expression when comparing SAGE tag expres-
sion values in different samples as explained in (15).
F parameter of DGED was chosen to be 1.5 to allow
detection of mild and consistent changes. For SAGE
COGENT analysis, long SAGE tags were trimmed to
short SAGE tags and analyzed together with short
SAGE libraries. For SAGE & microarray COGENT,
short or long SAGE tags were converted to Entrez Gene
IDs by using consensus tag mapping (‘Results’ section).
Tag-Seq data produces signiﬁcantly more signiﬁcant dif-
ferences (e.g.  10000 differentially expressed genes versus
 500 differentially expressed genes) when compared to
regular SAGE libraries due to very high tag counts. In
order to accommodate this restriction, we calculated the
average number of differential expression events in
non-tag-Seq datasets and took the same number of differ-
entially expressed genes or tags from tag-Seq datasets for
microarray & SAGE COGENT or SAGE COGENT.
We called this procedure rank selection.
RT–PCRs and tissue isolations
Brain tumor samples were collected at the Brain Surgery
Department of Cerrahpas¸a Hospital in Istanbul, Turkey
with informed consents from patients and under permis-
sion from Cerrahpas¸a Hospital’s ethical committee.
Non-tumor brain tissues were collected from epilepsy
surgeries. All tumor tissues were diagnosed and
non-tumor tissues veriﬁed to be normal by pathologists
Nucleic Acids Research, 2010,Vol.38, No. 20 7009at Cerrahpas¸a Hospital’s Pathology Department. Tissues
were fresh frozen within 30min of removal from brain.
RNA from brain tissues was extracted by using Qiagen
Rneasy Lipid Tissue Midi Kit. First strand cDNA synthe-
sis was performed with the Improm RT cDNA synthesis
system. RT–PCRs were performed using Taq Polymerase
(Fermentas). qRT–PCR reactions were carried out using
Fast-start sybGreen kit (Roche, cat# 03003230001), and
Roche Lightcycler 1.5. There is a high amount of ACTB
or GAPDH up-regulation in tumors when compared to
normals, as suggested by COGENT and veriﬁed in the
independent central nervous system (CNS) tumor panel
(Supplementary Figure S1). We therefore used S18 ribo-
somal RNA (Genbank accession: X03205) to normalize.
The expression relative to the average normal varied
between 0.67 and 1.28 in S18. This was a reasonable
interval when compared to that of ACTB which was
0.87–2.60. For the primers used for PCRs, please see
Supplementary Data.
Multi-cancer genes
Python scipy (scientiﬁc python) and matplotlib libraries
were used for the tests and graphs presented in Figure 3.
We used geneRIF database to scan gene related articles
which contains at least 1 geneRIF for  10000 genes (ap-
proximately half of the genes covered in this study).
To deﬁne a cancer geneRIF; we scanned the geneRIFs
for any of the ‘tumor’, ‘carcinoma’, ‘cancer’ or ‘neopla’
keywords.
When assigning a rank to genes to deﬁne the amount of
change in single cancer-normal comparison, we used the
lowest rank (highest change) in the case of multiple
probesets/tags. We used the Entrez Homologene
database to assign ortholog numbers.
To account for multiple hypotheses testing over genes
for microarray data we performed a Benjamini–Hochberg
correction as explained earlier. For SAGE data, we chose
a relatively stringent P-value (0.02) for the analysis pre-
sented. To calculate the false discovery rate (FDR) of
multiple hypotheses testing over samples we calculated
the expected number of false positives by a randomization
based approach which is based on randomly selecting X
number of genes from Y number of cancer types; where X
represents the number of genes altered in a certain cancer
type.
RIDGEs
We assigned a score to each gene by using an expression
matrix from the mean values of tumor and normal
samples from the microarray studies. We did not
consider SAGE data at this step in order to avoid
possible biases from merging two different types of data
distribution. The score is the average Spearman rank cor-
relation coefﬁcient (Rs) between the gene to be scored and
each neighboring gene within a±21 window size. Genes
with less than three expression data points were ignored in
the calculations. To deﬁne NA-RIDGEs, we used the
processed expression values from a wide histologically
normal human tissue expression study (GSE2361) from
Entrez GEO. (16)
To assign P-value thresholds to this average score
(to assess which scores are signiﬁcantly high), we
calculated the average Rs score for a gene with N
random genes from different chromosomes instead of
neighboring genes, where N represents twice the window
size. In order to optimize the window size, we repeated this
procedure for window sizes 2–48. We then picked 21 as the
optimum window size, because it maximizes the number
of RIDGEs and the number of genes above the threshold
does not increase any more after 21 (Supplementary
Figure S3).
Human genome version ‘hg180 from UCSC genome
browser was used in all analyses.
ICEBERG algorithm, zooming on RIDGEs
and G/C content
In order to assign member genes to each TA-RIDGE we
developed a double P-value approach to catch the iceberg
like structure of the TA-RIDGE. The ICEBERG algo-
rithm ﬁnds regions with at least one gene above a more
stringent P-value (primary P-value) and detects the genes
above a less stringent P-value (secondary P-value) in the
close vicinity (we selected one window size upstream and
two window sizes downstream as the proper neighborhood
as a good separator of nearby RIDGEs, after manual
curation of different possibilities). When working on dif-
ferential expression of genes in TA-RIDGEs we ﬁrst
assigned a score of over-representation of differential ex-
pression for each cancer, which calculates how common
differential expression would be in the same window size
when the same number of genes as altered gene count
are randomly selected from the corresponding probeset
collection (array platform or all available SAGE
to Entrez Gene ID mappings for short or long tag
mappings). The co-regulation P-value was calculated
with a similar randomization (e.g. arcs in RIDGE
drawings represent co-regulations with a P<0.002,
please see Supplementary Data for a detailed explanation
and the pseudocodes).
We calculated G/C content of the whole genomic region
of RIDGEs for the data presented in Table 2. G/C or GC/
CG content of the gene’s genomic region or the promoter
region ( 2000:+250, relative to transcriptional start site)
was calculated for the data presented in Supplementary
Figure S9. To select non-RIDGEs of varying window
sizes, we sought regions containing N consecutive genes
with non-signiﬁcant average Spearman scores (P>0.05)
where N stands for the window size of the non-RIDGE
region.
The melanoma metastasis dataset was adapted from
Entrez GEO record GSE8401 (17); which represents
RNAs of fresh frozen tissue samples from either primary
melanomas or melanoma metastasis samples.
RESULTS
We performed a gene and SAGE tag-centric meta-analysis
of cancer gene expression data in order to determine which
transcriptional units are common to multiple different
7010 Nucleic Acids Research, 2010,Vol.38, No. 20cancers. We named our methodology cognate gene expres-
sion patterning in tumors (COGENT—Figure 1). One of
the ways in which our ﬁndings differ signiﬁcantly from
previously published meta-analyses is that our datasets
comprise all major types of cancer: epithelial, hemato-
logical, central nervous system and connective tissue
tumors. Tumor names, classiﬁcations and datasets used
are listed in Supplementary Tables S1–4. In discussing
our results, change in cancer will mean the change
relative to corresponding normal unless otherwise stated.
We developed several methods in order to efﬁciently use
the data and to minimize false positives. Forty-three
percent of the short tag (14bp) mappings and 7% of the
long tag (21bp) mappings do not agree between single
mappings of SAGE Map and best gene calls of SAGE
Genie, the two most commonly used algorithms for
SAGE tag mapping (for detailed comparison of the two
algorithms; see Supplementary Data). In order to
minimize false positives, we restricted our analyses to
SAGE tags for which SAGE Map picked a single gene,
which also was the same as SAGE Genie’s best gene. We
call this method consensus tag mapping. A total of 68 and
80% of genes can be detected for short and long SAGE
tags, respectively, by consensus tag mapping. We further
selected 13 genes, all of which were assigned by consensus
tag mapping, and veriﬁed differential expression in an in-
dependent tumor–non-tumor brain tissue panel. RT–PCR
and Q-RT–PCR results were consistent with the
expression differences COGENT suggested (Figure 2,
Supplementary Figure S1 and Table S5). We also de-
veloped another method, rank selection, in order to in-
corporate SAGE data produced by tag-Seq. Brieﬂy, rank
selection equates the amount of differential expression in
tag-Seq data with the rest of datasets (See ‘Methods’ for a
more detailed explanation).
Multi-cancer genes
In ordertoidentifygenesthataredifferentiallyexpressedin
several types of tumors we analyzed a dataset where we
merged SAGE tags with microarray probesets using
Entrez Gene IDs (See Figure 1 and ‘Methods’ section).
To obtain the results presented hereafter, we used a
Q-value ﬁlter of 0.05 [Benjamini–Hochberg (13) corrected
P-value from student’s t-test as in (3)] for microarray
probesets, and a P-value of 0.02 together with an F-value
of 1.5 for SAGE tags [a Bayesian test described in (15)] for
deﬁning differential expression.
Interestingly (or expectedly, depending on one’s per-
spective) we found that genes that are over-expressed in
more types of cancers (multi-cancer genes) are also more
likely to have article annotations (assessed by having
annotated geneRIF: author entered summary of the
article; see (18) and http://www.ncbi.nlm.nih.gov/
projects/GeneRIF/) or being annotated as cancer related
SAGE data Microarray data
Pre-processing
and initial selection
Merge SAGE/microarray 
data when necessary
Key usage of the
COGENT dataset
DGED
find differentially expressed SAGE tags
short SAGE long SAGE tag-Seq
rank selection
consensus tag mapping
trimmed long SAGE
& short SAGE
Entrez gene IDs
pre-processing
omit ambigous mappings
find differentially expressed probesets
probesets from different platforms
COGENT
SAGE
COGENT
Microarray & SAGE
handle multiple mapping probesets
reveal multi-cancer genes
reveal multi-cancer gene signatures
reveal tumour-associated RIDGEs
reveal multi-cancer SAGE tags
Figure 1. Study design.
Figure 2. Veriﬁcation of oncoreveal predictions in an independent
panel of tumor and non-tumor brain samples. Veriﬁcation of nine
selected NYTA downregulated multi-cancer genes by RT–PCR.
Veriﬁcation of three selected NYTA upregulated multi-cancer genes is
presented at Supplementary Table S1. The corresponding COGENT
analysis for these genes is presented at Supplementary Table S5.
DNET: Dysmbryoplastic NeuroEpithelial Tumor.
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several keywords; Figure 3A, Supplementary Figure S2A
and Table S6). When FDR of the multi-cancer gene sig-
nature and enrichment probability of cancer geneRIFs are
considered, being over-expressed in more than 10 cancer
types seems like a reasonable threshold to deﬁne a
multi-cancer gene set (randomization based FDR=7%;
geneRIF enrichment P=0.002, cancer geneRIF enrich-
ment P=0.005, ranksums test; Figure 3A). There is not
a similar enrichment of geneRIFs for under-expressed
multi-cancer genes although FDR percent follows a
similar pattern (Supplementary Figure S2A).
Importantly, the genes which are common to all platforms
(N=1896) are signiﬁcantly enriched for geneRIFs and
AB
CD
Figure 3. Multi-cancer genes. (A) Multi-cancer genes are more likely to have been studied and have cancer annotations. X axis indicates gene sets
which are altered in more than a certain number of cancer types. Y axis indicates either FDR percentage or minus log P-value of the geneRIF
enrichment. We used only those genes which were common to all platforms in this analysis. (B) Rank of a gene’s expression change (in a single
cancer-normal comparison) decreases with the number of cancer types it is over-expressed in. To deﬁne rank, each cancer-normal comparison data
set is sorted by P-value for microarray data and ﬁrst by P-value and then fold value for SAGE data. The minimum rank (highest change) of a gene
was considered when multiple probesets mapped to a single gene. T-value is Kendall Tau B correlation coefﬁcient between X axis values and means
of each subgroup in the Y axis (P=0.00024). Highly signiﬁcant but smaller correlation exists when all data points rather than means are considered
(T= 0.09, P=6e 41). We used only those genes which were common to all platforms in this analysis. The expected distributions in B and D are
the randomly shufﬂed versions of the observed values to control for the within group sample size effect, if any. (C) Rank of a gene’s expression
change in a single cancer type explains being associated with cancer. Ranks of the TA and not yet TA genes are signiﬁcantly different for most of the
X axis values (no. of cancer types), and when the data is not sub-divided by the X axis (P<0.000000, Mann–Whitney U-test; data not shown). All
genes are used in the analysis. (D) Over-expressed multi-cancer genes have more orthologs (homologs in different species). T-value is Kendall Tau B
correlation coefﬁcient between X axis values and means of each subgroup on the Y axis (P=0.025). A signiﬁcant but smaller correlation exists when
all data points rather than means are considered (T=0.06, P=1.46e–05). We used only those genes which were common to all platforms in this
analysis. *P<0.05, **P<0.01, ***P<0.005. P-values are of two independent samples t-test. In all of the graphs, the point markers are means of the
data, and the error bars indicate standard error.
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Therefore, genes common to all platforms were used
where this platform bias would affect results.
Genes that show higher expression changes in single
cancer types also tend to change more in multiple
cancers (Figure 3B and Supplementary Figure S2B).
Multi-cancer genes are thus more likely to be associated
with cancer; and this is true for many which are familiar,
well-studied cancer genes (TP53, EGFR, ERBB2, VEGFA,
PTGS2, BRCA1, CDKN2A, ESR1, PTEN, CCND1 and
HIF1A; Supplementary Table S7A). We were however
intrigued to also ﬁnd numerous multi-cancer genes with
no previous cancer annotation (e.g. SYNCRIP, P4HA1,
GART and ASCC3; see Supplementary Table S7B for a
representative list. For a more comprehensive analysis of
multi-cancer genes, see www.oncoreveal.org or
Supplementary Excel ﬁle). A total of 794 genes are
over-expressed in more than 10 different types of cancers
(FDR=7.1%), but 437 of these do not have any cancer
geneRIFs. A total of 212 genes are over-expressed in more
than 13 types of cancers (FDR=0.4%), 110 of them not
being associated with cancer (See Supplementary Table S6
for detailed statistics). These NYTA genes differ in their
rankings in single studies from TA multi-cancer genes. In
general, a gene is probably already associated with cancer
if it ranks high in a single type of cancer (Figure 3C and
Supplementary Figure S2C), but multi-cancer genes that
have lower rankings are less likely to have been studied.
These results indicate the utility of COGENT, which
enabled us to discover genes related to cancer in
multiple cancer types, but which had not previously
been linked with cancer due to their lower rankings in
single studies.
We also functionally classiﬁed all multi-cancer genes
which are differentially expressed in more than 10 cancer
types. As expected, the entire set of over-expressed
multi-cancer genes are signiﬁcantly enriched (DAVID:
Benjamini–Hochberg<0.05) (19) for cancer related func-
tions such as cell cycle and apoptosis (see Supplementary
Table S8A for the top 50 enriched classes). In terms of
signaling pathways, over-expressed multi-cancer genes are
signiﬁcantly enriched for TP53 and extra-cellular matrix–
receptor interaction and focal adhesion genes (64 genes;
 8% of all) whereas under-expressed multi-cancer genes
are enriched for ErbB signaling, calcium signaling and
long-term potentiation genes (45 genes;  10% of all)
(Supplementary Table S8B,C). On the other hand,
over-expressed NYTA multi-cancer genes are enriched
for endoplasmic reticulum genes (46 genes;  12% of all)
and phosphoproteins (168 genes;  39% of all) whereas
under-expressed NYTA multi-cancer genes are enriched
for alternatively spliced genes (132 genes;  42% of all)
and phosphoproteins (124 genes;  40% of all)
(Supplementary Table S8D, E). When the background
gene set is set to TA multi-cancer genes rather than the
whole genome, NYTA over-expressed multi-cancer genes
are enriched only for endoplasmic reticulum genes
(Supplementary Table S8F). COGENT detected 46 endo-
plasmic reticulum NYTA genes as over-expressed in a
wide variety of tumors (data not shown). A similar com-
parison of under-expressed NYTA multi-cancer genes to
TA ones did not reveal any signiﬁcantly enriched function-
al category. This indicates that endoplasmic reticulum
genes are not as studied as their importance in cancer
would suggest.
Another important ﬁnding of COGENT illustrates the
dysregulation of ribosomal proteins. 121 ribosomal
protein encoding genes are over-expressed at least in two
types of tumors while 92% of these are also
under-expressed in at least one tumor. A ribosomal
protein gene subset consisting of RPS16, RPL15,
RPL31, RPS15A, RPL22 and RPS6 was under-expressed
in more than seven types of tumors, as well as being
over-expressed in many tumors (Supplementary Excel
ﬁle). RPL18A is an example of a ribosomal protein that
is mainly under-expressed (under-expressed in six types of
tumors) while being over-expressed in only two types
(astrocytoma grade 2 and 3).
We also observed a trend of over-expressed
multi-cancer genes having more orthologs (Figure 3D)
whereas under-expressed multi-cancer genes having
fewer orthologs (Supplementary Figure S2D). This result
is not surprising considering that genes more strictly
conserved throughout evolution are more likely to be
involved in core-processes affected during tumorigenesis
regardless of tissue context.
In addition to identifying multi-cancer genes, we
isolated potentially important multi-cancer SAGE tags.
This approach revealed SAGE tags that have probably
not been included in single studies because users tend to
ignore multiple mapping or ambiguously mapping tags. If
such an ambiguous SAGE tag is differentially expressed in
many types of tumors, identifying that tag’s correspond-
ing gene(s) might be worth the effort. For instance, seven
over-expressed and 58 under-expressed SAGE tags occur
in more than three types of tumors but do not reliably
map to a gene by either SAGE Map or SAGE Genie
(see detailed statistics in Table 1).
RIDGE analysis
Considering previous ﬁndings which indicate co-regulated
genomic regions (11) in different cancers, we strove to
identify multi-cancer regions of increased co-regulation
(RIDGEs) in comparison to RIDGEs associated to vari-
ation among normal tissues (NA-RIDGEs). We used
the Spearman rank correlation coefﬁcient to compare
expression of neighboring gene pairs as the co-regulation
metric. To assign members to each RIDGE, we developed
an algorithm which we named ICEBERG algorithm (See
‘Methods’ for detailed explanation). By using a primary
P=0.002 and secondary P=0.05; the ICEBERG algo-
rithm identiﬁed 81 TA-RIDGEs and 83NA-RIDGEs.
This corresponds to 10.9% of all the genes studied (2242
of 20433) being located in either TA-RIDGEs (1124
genes) or in NA-RIDGEs (1364 genes). A landscape of
RIDGEs on two representative chromosomes is presented
at Figure 4A. Roughly half of the clusters (N=45) were
both TA- and NA-RIDGEs, indicating co-regulation of
these regions irrespective of the cancer status of the cell.
To investigate the presence of paralogs in RIDGEs, we
deﬁned a ‘family gene’ as a gene in a RIDGE which has at
Nucleic Acids Research, 2010,Vol.38, No. 20 7013least one more family member in the same RIDGE,
inferring family membership from the similarity of gene
symbols. In total 20% of the TA-RIDGEs consist of
>50% ‘family genes’ (see Supplementary Figure S4A for
the histogram). On the other hand, 40% of the
TA-RIDGEs did not have any ‘family genes’. This
suggests that only a fraction of RIDGEs can be explained
by larger groups of paralogs for which co-regulation
might be a consequence of recent gene duplication
events. Another useful score, ‘normal co-regulation per-
centage’ is the fraction of those genes on TA-RIDGEs
which are also co-regulated among normal tissues
(P<0.05). According to the ‘normal co-regulation per-
centage’ density distribution, 30% of large TA-RIDGEs
(RIDGEs containing ten or more genes) and 40% of all
TA-RIDGEs display <20% normal co-regulation, i.e.
they are tumor speciﬁc (See Supplementary Figure
S4E–F). Figure 4B presents a selection of RIDGEs that
vary in ‘family gene’ and ‘normal co-regulation percent-
ages’. Importantly, RIDGE analysis also revealed that
41% and 83% of the genes on the Y chromosome
belong to a TA-RIDGE or an NA-RIDGE, respectively
(Figure 4B).
Cancer speciﬁc RIDGEs tend to be less paralog dense
when compared to global RIDGEs (i.e. TA-RIDGEs
overlapping with NA-RIDGEs). In other words, paralog
RIDGEs tend to be co-regulated both among normal
tissues (NA-RIDGEs) and cancer (TA-RIDGEs) (chi
square P=0.0284 when paralog RIDGE thresh-
old=30% and normal co-regulation percentage=30%;
Supplementary Table S9).
Taken overall, these results suggest a prevalent mech-
anism of gene regulation in cancer related gene expression
in multiple cancers, based solely on the physical location
of genes in cancer-speciﬁc TA-RIDGEs.
A new subclass of keratin genes, an example ﬁnding by
zooming on RIDGEs
We present one example ﬁnding of RIDGE analysis which
points to a subgroup of seven keratin genes [KRT5, KRT6
(A, B and C), KRT14, KRT16 and KRT17] which are
over-expressed in non-melanoma skin cancers (NMSCs),
but are almost completely turned off in melanoma metas-
tasis. This subgroup is over-expressed in squamous cell
skin cancer (SCSC), as well as in basal cell skin cancer,
but is signiﬁcantly more downregulated in melanoma me-
tastasis relative to primary melanoma (Figure 5B). In
addition, the SPRR and S100A gene families which
reside in the EDC are also regulated in approximately
the same manner (Figure 5A and B). In fact, of all the
genes in the entire EDC, over-expression in NMSCs is
conﬁned solely to S100A and SPRR genes (Figure 5A,
lower panel).
Other examples and dynamics of RIDGEs
Some paralog TA-RIDGEs are also informative for
cancer research. Metallothionein TA-RIDGE
(Supplementary Figure S5), Histone 1 cluster
TA-RIDGE (Supplementary Figure S6) and MHC Class
II TA-RIDGE (Supplementary Figure S7) are differential-
ly expressed in many cancers (see ‘Discussion’ section for
further comments). Furthermore, a clear under-expression
is observed in three different types of lymphomas at the
MHC TA-RIDGE. Looking at the data from a different
perspective, we analyzed the frequency of signiﬁcant
(P<0.01) co-regulations among different cancers using
all 81 TA-RIDGEs. As expected, different grades or
states of the same cancers [e.g. astrocytoma grade 2
versus astrocytoma grade 3 or chronic phase and
accelerated phase of chronic myeloid leukaemia (CML)]
were among top co-regulated cancer types, as well as dif-
ferent types of hematological cancers (Supplementary
Table S10).
Since most of the co-regulated regions of the genome we
point out here are not well characterized, it was not
possible to attach a signiﬁcant functional meaning to the
existence of non-paralog TA-RIDGEs. Nevertheless, we
observed signiﬁcant differential expression in tumors
within many non-paralog TA-RIDGEs. For instance,
Chr8_NAPRT1 (named after the leftmost gene in the
RIDGE) at one end of the eighth chromosome is
over-expressed in a variety of tumors including epithelial,
CNS and hematological (Figure 4B and Supplementary
Figure S8).
There is no commonality (i.e. enriched functional
classes) among the genes at non-paralog RIDGEs other
than high genomic G/C and GC/CG content.
Chr8_NAPRT1 is a good example of such a
TA-RIDGE with 63% average genomic G/C content
that appears as a clear outlier on chromosome 8
(Supplementary Figure S8). Indeed, we found that G/C
rich regions are associated with RIDGEs in general.
When analyzing G/C content of RIDGEs (whole
genomic region including intergenic regions), we used a
previously established classiﬁcation; isochores [(20) and
Table 2] to deﬁne G/C content classes. TA-RIDGEs are
Table 1. SAGE tags revealed by COGENT
Over-expressed tags Under-expressed tags
No. of cancer types
a Single 2 and 3 >3 Single 2 and 3 >3
Tags with ambigous gene mapping 3558 1522 639 2974 1419 707
Tags which don’t map to reliable 30ends
b 508 92 7 496 159 58
Tags which don’t map to any existing cDNA sequence 19 2 0 23 8 2
aBeing differentially expressed in this many number of cancer types when compared to corresponding normals.
bTags which map to reliable 30ends are used in routine SAGE data analysis. SAGE Map’s polyadenylated mammalian gene collection (MGC),
RefSEQ, mRNA or EST called tags and SAGE Genie’s reliable 30end calls (tags which are present at the most 30 NlaIII site and come from a
transcript with either polyA signal or polyA tail) were used to build reliable 30 end tag sets.
7014 Nucleic Acids Research, 2010,Vol.38, No. 20enriched for H3 class (highest G/C content, G/C>53%)
3.8-fold relative to non-RIDGE windows (chi-square
P=0.0129). More strikingly, non-paralog TA-RIDGEs
are enriched for H3 class 7.0-fold relative to
non-RIDGE windows (chi-square P=0.0001). Overall,
43% of the TA-RIDGEs correspond to high G/C
content genomic regions (deﬁned by H2 and H3 isochores:
G/C%>46%) which corresponds to a signiﬁcant
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Position on the chromosome (Mb)
A
Figure 4. Overview and close up of TA-RIDGEs and NA-RIDGEs by using gene neighborhood correlation score. (A) Two representative chromo-
somes (upper—chr1; lower—chr17) which summarize the overall appearance of TA-RIDGEs and corresponding gene neighborhood correlation
scores (average of Rs with ± 21 neighboring genes) with normal variation expression matrix. Darker dots were identiﬁed as being member of a
TA-RIDGE by the ICEBERG algorithm. The TA-RIDGEs were named by using the chromosome they reside in and the leftmost member of the
TA-RIDGE. Dashed lines represent the secondary P-value cut-off and primary P-value cut-off respectively from low to high in the Y axis. X axis
represents position in megabases (MB). (B) Six representative TA-RIDGEs. Axes are as in (A). Family gene % (percentage of genes which have at
least one family member in the same RIDGE) and normal co-regulation % (the % of genes at a TA-RIDGE that score above the P0.05 threshold at
the corresponding region from the normal variation expression matrix) are shown under each TA-RIDGE. Chr5_PCDHAC1, Chr17_Krt25 are
examples of family gene dense TA-RIDGEs, which comprise 28% of all TA-RIDGEs. Chr16_HBQ1 is a non-family RIDGE which is common to
cancer and normal context. chr7_C7orf28A and chr7_SSPO are two examples of cancer speciﬁc TA-RIDGEs, which comprise 40% of all
TA-RIDGEs. Almost the entire chromosome Y is co-regulated among normal tissues and also in cancer and identiﬁed as one TA-RIDGE:
chrY-RPS4Y1.
Nucleic Acids Research, 2010,Vol.38, No. 20 70151.72-fold enrichment when compared to non-RIDGE
regions of varying window sizes (chi-square P=0.019
when compared to non-RIDGEs with window size of 19
and P=0.0104 when compared to non-RIDGEs with
window size of 27). A similar enrichment was seen for
NA-RIDGEs as well (Table 2). In addition, both the
genomic regions and the promoter regions of genes in
non-paralog TA-RIDGEs have signiﬁcantly more GC/
CG pairs when compared to either other RIDGEs or
non-RIDGE regions (Supplementary Figure S9).
Overall, though G/C richness is a general phenomenon
that comprises 43% of the TA-RIDGEs and 40% of
NA-RIDGEs, non-paralog RIDGEs tend to be more
G/C and GC/CG rich than both non-RIDGE regions
and other RIDGEs.
Online service for the analysis of multi-cancer genes and
multi-cancer RIDGEs
We present a PHP/MySQL based online service in order
for the research community to browse and ﬁlter the sets of
multi-cancer genes and TA-RIDGEs (available at
http://www.oncoreveal.org). Users are able to analyze
both their own data and COGENT-SAGE, COGENT-
microarray & SAGE data compiled from public domain
and TA-RIDGEs interconnected with the COGENT
browser module (Figure 6). Several ﬁltering, sorting and
exporting options are available at the web service, as well
as the ability to overlay gene or tag lists. A unique
property of oncoreveal is that users can create complex
gene signatures by specifying complex queries. For
instance, one can ﬁlter for all genes that are speciﬁcally
over-expressed in more than ﬁve of glial cell cancers, while
not under-expressed in any other cancer. Or, one can
easily ﬁnd cell cycle genes which are over-expressed in
melanomas but not other types of skin cancers.
Furthermore, users can visualize RIDGEs with the
broad chromosome view (as in Figure 4) or the differential
expression view (as in Figure 5).
DISCUSSION
In this study, we present a meta-analysis of gene expres-
sion in cancer by utilizing both SAGE and microarray
data. The majority of signiﬁcant differences were caught
by microarray studies due to their larger sample size
(148139 microarray probesets versus 17831 SAGE tags),
but including SAGE data increased the overall signiﬁ-
cance of the observations as well as the tumor type
coverage. For 13 tumor types, mostly CNS tumors, we
had only SAGE data available.
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Figure 4. Continued.
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Figure 5. Regulation of Keratin, SPRR and S100A gene families in skin cancer and melanoma metastasis. (A) There are two large keratin
TA-RIDGEs on the genome on chr12 and chr17 almost all of which are down-regulated in squamous cell and basal cell skin cancer when
compared to normal skin. However; KRT5, KRT6A, KRT6B and KRT6C (on chr12, shaded gray) and KRT14, KRT16 and KRT17 (on chr17,
shaded gray) are up-regulated in SCSC and four of them are also upregulated in basal cell skin cancer. The TA-RIDGE which corresponds to the
EDC that contains SPRRs (shaded red) and S100As (shaded blue) is mostly upregulated in both types of NMSC. All three gene families are
over-expressed in chronic phase CML as well. Different colors represent different tumors. Each colored box represents differential expression with
the merged COGENT data set (Q<0.05 for microarray, P<0.02 for SAGE). Light gray boxes represent non-differential expression. Cross-dashed
boxes represent missing data. Cancers are sorted by the fold enrichment of differential expression over the expected random differential expression, as
explained in Supplementary Data. Fold enrichment values are stated in parentheses beside the tumor names. Only cancers that are signiﬁcantly
(randomization based test: P<0.01) enriched for differential expression are shown. The arcs between rows represent signiﬁcant co-differential
expression events (red arcs: P<0.001, black arcs: P<0.002). Cancers are divided into two by the presence or absence of a signiﬁcant co-regulation
with another cancer. Genes annotated with *** are signiﬁcantly (P<0.05) co-regulated with the neighbors. Close-ups of RIDGEs with different
ﬁlters can be visualized at www.oncoreveal.org. (B) SPRR genes, S100A genes and Keratin genes which are over-expressed in SCSC (red squares in
A) are among the top down-regulated genes in melanoma metastasis samples when compared to primary melanoma samples. Each bar in the bar
graph represents the fold change between average expression values of two classes. Error bars represent the average of standard deviations over all
possible fold changes between two classes divided by size of all possible comparisons. ***P<0.001 by Mann–Whitney U test. Inset: distribution of
fold changes presented in the main graph. Boxes represent inter-quartile range. Whiskers span 1.5 times inter-quartile range.
Nucleic Acids Research, 2010,Vol.38, No. 20 7017Our ﬁndings highlight many multi-cancer genes that
have not yet been studied, which is particularly important
due to the fact that over-expressed genes often present
feasible drug targets and under-expressed multi-cancer
genes may represent important gene therapy candidates.
These NYTA multi-cancer genes change signiﬁcantly
between cancer and normal tissues, but they rank lower
than already discovered multi-cancer genes. At ﬁrst
glance, this might be interpreted to imply that NYTA
multi-cancer genes are less important in cancer. This con-
clusion would be wrong. It is entirely possible that genes
with a smaller magnitude of change in expression level
with small variance among many cancer types may play
as important a role in tumorigenesis as high magnitude
changes with small variance. At the same time, the small
magnitude of change in expression helps to explain why
these genes have not yet been studied as cancer genes.
Enrichment of phosphoproteins and alternatively
spliced genes among NYTA multi-cancer genes is inform-
ative but not surprising due to the established variability
and disturbance of cellular machinery in cancer.
COGENT also points to 46 over-expressed NYTA
multi-cancer genes which are functionally located in the
endoplasmic reticulum. Although the endoplasmic reticu-
lum is not known to be involved in cancer, related ER
genes have been directly or indirectly associated to
multiple cancer related pathways such as apoptosis or
angiogenesis (21). Changes in the endoplasmic reticulum
may also contribute to more global effects on cell surface
properties important for immune recognition of cancer
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Figure 5. Continued.
Table 2. GC rich regions are more likely to be co-regulated
L1 L2 H1 H2 H3
TA-RIDGEs (81) 6.2 21.0 29.6 37.0 6.2
Non-paralog TA-RIDGEs (family gene % <20) (45) 8.9 22.2 26.7 31.1 11.1
NA-RIDGEs (83) 3.6 27.7 28.9 30.1 9.6
Non-RIDGEs (window size 19) (494) 5.9 29.8 37.0 25.5 1.8
Non-RIDGEs (window size 27) (291) 5.2 33.7 35.7 24.1 1.4
Values show frequency of RIDGEs among all RIDGEs. Letter designation represents isochore classiﬁcation by G/C content. G/C content is
calculated by considering the whole genomic region of the RIDGE. L1<37%, 37%   L2<41%, 41%   H1<46%, 46%   H2<53%, H3  
53%. Numbers in the parentheses stand for number of RIDGEs.
7018 Nucleic Acids Research, 2010,Vol.38, No. 20cells. Over-expression of another class, ribosomal genes, is
generally attributed to an increased cell proliferation rate
as a result of increased metabolic activity in tumors, and
generally deemed functionally irrelevant. Viewed in this
light, the downregulation of these particular genes may
be pointing to an altogether different effect. Although
there are several ﬁndings which suggest functional rele-
vance for the differential expression of ribosomal
proteins, such as regulation by p53, RB, MYC and
PTEN (22), COGENT’s pointing to occasional under-
expression of ribosomal genes among multiple cancer
types remains engrossing and intriguing.
Co-regulated regions have been studied in many differ-
ent contexts including cancer. To our knowledge, ours is
the ﬁrst study that compares TA- and NA-RIDGEs in
order to determine cancer-speciﬁc TA-RIDGEs. One
concern is to accurately assign the boundaries of a
RIDGE, which we approached by using the ICEBERG
algorithm. Another is that using different expression
matrixes will lead to identiﬁcation of different RIDGEs.
For instance, 27 of 81 TA-RIDGEs were also identiﬁed as
RIDGEs in the study by Stransky et al. (11) (at least one
gene was commonly identiﬁed as being signiﬁcantly
co-regulated). Common RIDGEs included MHC Class
II, S100A family and Histone cluster 1. There are
several hypotheses that might explain the occurrence of
RIDGEs, such as genomic ampliﬁcations/deletions,
epi-genetic regulations and a regional lack of DNA
repair. In the bladder cancer context of Stransky et al.
(11), genomic ampliﬁcations/deletions detected by the
comparative genomic hybridization (CGH) method
turned out to explain some fraction of the RIDGEs, but
not all. In this study, we point to a signiﬁcant association
between RIDGEs and G/C and GC/CG rich regions. This
ﬁnding is consistent with previous SAGE experiments
which showed that G/C rich regions are highly expressed
in normal tissues (23). In addition, G/C richness of
RIDGEs might reﬂect several different underlying
regulation mechanisms such as chemical fragility, DNA
motifs or methylation of DNA through GC/CG
dinucleotides.
Keratins are intermediate ﬁlament proteins which
are well established epithelial cell markers and EDC
genes are epidermal differentiation markers. Down-
regulation of differentiation markers in a more cancerous
state is expected due to stem cell-like state of tumors.
However, over-expression in NMSCs when compared to
normal skin and differential down-regulation in
melanoma metastasis of the genes which are
over-expressed in NMSC suggests new functional roles
for seven keratin genes of separate functional classes
[KRT5 and KRT6 are type II epithelial keratins and
KRT14, KRT16 and KRT17 are type I epithelial keratins
(24)], SPRRs and the S100A gene family. Keratins are
starting to be associated with diseases (24) which
suggests new functions such as K170s effect on cell
growth (25) or K80s and 180s necessity for melanoma
invasion (26). SPRRs are keratinocyte differentiation
markers (27) which are known to contribute to the forma-
tion of the corniﬁed envelope of skin cells (28). Although
SPRRs’ role in tumorigenesis is not known, they are
over-expressed under stress conditions which might
explain their up-regulation in NMSCs (28). One member
of the family, SPRR3, acts like a tumor suppressor on
esophageal squamous cell carcinoma cells (29). S100
proteins are already associated with cancer, such as
S100A2 (30) and S100A4 (31) which have been associated
with tumor cell motility and metastasis. A melanoma me-
tastasis to primary melanoma comparison might reﬂect
the differences between real melanoma cells and other
skin components due to selection in the metastasis site
and probable mixture of cell types at the primary
source. However, this probability does not decrease the
importance of the presented co-regulation of different
gene families. At most it might affect further interpret-
ation of this ﬁnding, if true.
Cogent SAGE analysis Cogent SAGE&microarray analysis
User data overlay SAGE tag list
DGED result
Entrez Gene IDs
Entrez Gene symbols
www.oncoreveal.org
RIDGE analysis
NA
26 tumour types
Organ/tissue source based (N = 18)
Major tumour types
Different thresholds
49 tumour types
Organ/tissue source based (N = 27)
Major tumour types
Different thresholds
49 tumour types
NA NA Tag mapping
Filtering
Other
No mapping
SAGE Genie or SAGE Map
Consensus tag mapping
Gene Ontology, KEGG
Folds of differential expression
Genomic location
Chromosome based
Broad chromosome view
Differential expression view
Selection of fields to be visualized
Sorting (with different options)
Data export
Cancer type
filtering
Figure 6. Online service; www.oncoreveal.org. Users can analyze COGENT SAGE, COGENT microarray & SAGE and TA-RIDGEs by using
oncoreveal. Short SAGE tags or DGED results for COGENT–SAGE and Entrez Gene IDs or symbols can be used as input. Users can ﬁlter altered
genes by cancer type (with any of the three different classiﬁcations) or number of cancer types in which change occurred. Several different ﬁltering
options from commonly used data sources such as gene ontology and different visualization, sorting and export options are available.
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Although the view on MHC Class II proteins is that they
are generally not expressed on tumor cells, they are known
to be over-expressed in several tumors (32) such as
gliomas, and some tumor cells can be recognized by
CD4+ T cells due to the presence of MHC Class II
based antigen presentation (33). Furthermore, to the
best of our knowledge, the under-expression of MHC
Class II proteins in lymphomas is not an established
fact, in spite of supporting evidence such as lack of detec-
tion of HLA-DR in diffuse large cell lymphoma patients
as a sign of shorter survival (34). The histone RIDGE also
resides on the same chromosome. There is a considerable
amount of data about the effect of post-translational
modiﬁcations of histone proteins such as deacetylation
or methylation which in turn epi-genetically regulate
gene transcription. However, there are few examples of
histone proteins which are related to cancer directly (35).
Indeed, none of the histone genes show a cancer geneRIF
and the majority of the histone genes do not have any
geneRIFs at all (38 of 47 histone genes). Histone
proteins are expressed from four different clusters in the
human genome (Histone clusters 1–4). In total, 66 histone
genes reside at histone cluster 1. Every class of ﬁve differ-
ent histone proteins (H1-H2A, H2B, H3 and H4) is ex-
pressed from this cluster. In histone cluster 1, mainly
histone 1 (e.g. HIST1H1T) and histone 2 (e.g.
HIST1H2BC, HIST1H2AC and HIST1H2BD) genes
are over-expressed in cancer tissues (Supplementary
Figure S6). The signiﬁcant alteration of histones in
multiple tumors is likely to be functionally relevant in
tumorigenesis.
Approximately half of the RIDGEs did not arise from
paralog genes. One possibility is that the differential ex-
pression events at these RIDGEs are just side-effects of a
previously important key tumorigenic event. Another pos-
sibility is that only some of the genes within these
RIDGEs contribute to the key processes during tumori-
genic transformation. For instance, TNF is co-regulated
with its neighbors (chr6_CDSN). Some other TA genes
within the non-paralog RIDGEs with most cancer
geneRIFs are RHOA, MAPK3, CYP2E1, RELA, GJA1,
DAPK1, CCKBR, FASN, GPX1 and HSPB1. It might be
possible that if a gene is being regulated together with a
well known cancer gene, it is also functionally important
in tumorigenesis.
Oncoreveal has several novel utilities when compared to
similar existing tools such as Oncomine. Oncoreveal
allows an unlimited size of user gene/tag list overlays. It
allows SAGE data analysis in addition to the SAGE-
microarray merged data analysis by allowing users to
use or omit consensus tag mapping. Moreover, oncoreveal
enables RIDGE analysis by offering basic ﬁltering options
as a starting point as well as detailed visualization options.
In our opinion, having most of the data presented in this
study available, browsable and ﬁlterable online makes this
data as informative as possible and is likely to lead to new
discoveries which we have not had an opportunity to
reveal with our analysis.
In conclusion, our study revealed a set of previously
unstudied multi-cancer genes that are differentially
expressed in as many tumors as established cancer genes.
We also investigated TA-RIDGEs in comparison with
NA-RIDGEs which appeared to coincide with GC rich
regions of the human genome. In addition to presenting
several examples of RIDGE analysis, we present an online
tool, oncoreveal, for researchers to analyze multi-cancer
genes/tags and TA-RIDGEs. We believe that, especially
with the availability of new generation high-throughput
methods, analysis of RIDGEs, multi-cancer genes and
multi-cancer gene signatures is now more feasible and
will add considerably to our knowledge about tumorigen-
esis, which will eventually lead to efﬁcient diagnosis and
treatment.
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Supplementary Data are available at NAR Online.
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